A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes
Authors:
- R. EvansRER. Evans
- S. TanakaSTS. Tanaka
- S. TounoSTS. Touno
- K. ShimizuKSK. Shimizu
- S. SakuiSSS. Sakui
- J. WuJWJ. Wu
- H. FaesselHFH. Faessel
- Y. HangYHY. Hang
- R. AlexanderRAR. Alexander
- L. RosenLRL. Rosen
- D. HartmanDHD. Hartman
- 1 December 2019
- journal article
- Published by Elsevier in Sleep Medicine
- Vol. 64, S105-S106